What is the CVSS score of CVE-2023-38954?

CVE-2023-38954 has a CVSS 3.1 base score of 9.8 (Critical). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H. EPSS exploitation probability: 0.5%.

Bioaccess Ivs CVE-2023-38954

CRITICAL

SQL Injection (CWE-89)

2023-08-03 cve@mitre.org

SQLi Bioaccess Ivs

9.8

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

9.8 CRITICAL

AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Attack Vector

Network

Attack Complexity

Low

Privileges Required

None

User Interaction

None

Scope

Unchanged

Confidentiality

High

Integrity

High

Availability

High

Lifecycle Timeline

CVE Published

Aug 03, 2023 - 02:15 nvd

CRITICAL 9.8

DescriptionNVD

ZKTeco BioAccess IVS v3.3.1 was discovered to contain a SQL injection vulnerability.

AnalysisAI

ZKTeco BioAccess IVS v3.3.1 was discovered to contain a SQL injection vulnerability. Rated critical severity (CVSS 9.8), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as SQL Injection (CWE-89), which allows attackers to execute arbitrary SQL commands against the database. ZKTeco BioAccess IVS v3.3.1 was discovered to contain a SQL injection vulnerability. Affected products include: Zkteco Bioaccess Ivs.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Use parameterized queries/prepared statements. Never concatenate user input into SQL. Apply least-privilege database permissions.